Hims & Hers price target raised to $28 from $24 at Canaccord
PremiumThe FlyHims & Hers price target raised to $28 from $24 at Canaccord
5d ago
Hims & Hers Health Reports Strong Q3 2024 Growth
Premium
Company Announcements
Hims & Hers Health Reports Strong Q3 2024 Growth
5d ago
Closing Bell Movers: Palantir jumps 13% after results
Premium
The Fly
Closing Bell Movers: Palantir jumps 13% after results
5d ago
Hims & Hers sees Q4 revenue $465M-$470M, consensus $421.1M
PremiumThe FlyHims & Hers sees Q4 revenue $465M-$470M, consensus $421.1M
5d ago
Notable companies reporting after market close
Premium
The Fly
Notable companies reporting after market close
5d ago
Hims and  Hers Health options imply 17.0% move in share price post-earnings
Premium
The Fly
Hims and Hers Health options imply 17.0% move in share price post-earnings
5d ago
FDA not planning to take action against GLP-1 compounders, Endpoints says
PremiumThe FlyFDA not planning to take action against GLP-1 compounders, Endpoints says
22d ago
Jefferies says ‘all data signs point to 3Q beat’ for Hims & Hers
Premium
The Fly
Jefferies says ‘all data signs point to 3Q beat’ for Hims & Hers
26d ago
BTIG says market demand for lower cost GLP1-s should benefit LifeMD, Him & Hers
Premium
The Fly
BTIG says market demand for lower cost GLP1-s should benefit LifeMD, Him & Hers
26d ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100